← All trials
NCT01208766
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2011
- Primary completion
- Apr 1, 2021
- Completion date
- Apr 1, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 1500
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- HOVON - Dutch Haemato-Oncology AssociationLead sponsor
- HOVON - Dutch Haemato-Oncology AssociationOverall official - principal investigator
- European Myeloma NetworkCollaborator
- Central European Myeloma Study GroupCollaborator
- Nordic Myeloma Study GroupCollaborator
- Gruppo Italiano Malattie EMatologiche dell'AdultoCollaborator
- Deutsche Studiengruppe Multiples MyelomCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.